Can-Fite Completes Dosing in Phase III Psoriasis Cohort; Interim Data Due Q1 2027
CANF is trading near its 52-week low of $1.42 (9.2% above the low) on light trading volume (0.1× avg).
Summary
Can-Fite finished dosing all 247 patients in the interim-analysis cohort of its pivotal Phase III psoriasis trial, with IDMC interim results now expected in Q1 2027.
Key Events · Product Development and Regulatory · CANF
-
Phase III Psoriasis Dosing Complete
The last patient in the interim-analysis cohort received the final dose, completing treatment of the first 247 patients in the pivotal Phase III study of oral Piclidenoson for moderate-to-severe plaque psoriasis.
-
Interim Readout Guided to Q1 2027
Results of the pre-specified interim analysis are expected to be read out by the Independent Data Monitoring Committee in Q1 2027, evaluating PASI 75 and sPGA 0/1 co-primary endpoints at Week 16.
-
FDA- and EMA-Agreed Protocol
The randomized, double-blind, placebo-controlled study is being conducted under a protocol agreed with both the U.S. FDA and the European Medicines Agency, with patients receiving Piclidenoson 3 mg or placebo twice daily.
-
Capital Needs Remain a Risk
The filing's risk factors reiterate Can-Fite's history of losses and need for additional capital to fund operations, plus risk of not satisfying NYSE American continued listing requirements.
Analysis · CANF · Life Sciences
The operational path to the interim readout is now clear: Can-Fite's lead drug Piclidenoson has finished dosing the 247 patients that make up the pre-specified interim-analysis cohort of its pivotal Phase III psoriasis trial, run under a protocol agreed with both the FDA and EMA. The Independent Data Monitoring Committee is expected to deliver those interim results in Q1 2027. For a company this small, the readout is effectively the whole investment case. A positive interim result keeps the program — and the company's ability to raise money — alive, while a miss would leave it with a thin pipeline and a history of losses and ongoing capital needs that the filing itself flags as risks. Nothing here changes the financial picture today; it moves the binary event one step closer.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CANF was trading at $1.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $1.42 to $12.30. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.